Mediso Launches Next Generation MRI Spectrometer spinScan®

Mediso released their next generation MRI spectrometer spinScan® the successor to the previously used console in the nanoScan® MRI product line. The new spectrometer was optimized for MRI applications delivering an ultra-low-noise expandable RF front-end and real-time dynamic shimming.

The spectrometer is interfaced with three Mediso developed software applications to deliver a complete MRI workflow: the Sequence Development Platform for absolute control over the pulse sequences and reconstruction algorithms, the FDA approved and clinically validated InterView™ FUSION and Nucline™ for routine acquisition planning, reconstruction, image post-processing and evaluation.

Gergő Bagaméry, Director of Preclinical Product Development at Mediso commented: “Our main goal was to have a dedicated MRI spectrometer that is optimized for image quality, and works seamlessly with our clinically validated software platforms. We believe it is a big jump in performance for our research scanners as well as perfect platform for a potential clinical / OEM product line.”

The spinScan® spectrometer is based on a technology that has been continuously developed for 10+ years, featuring an FPGA SoC platform with highly scalable transceiver architecture enabling more than 128 receiver channels and microsecond gradient resolution with closed-loop control via high-speed optical interfaces. Eddy current compensation is realized through digital cross term pre-emphasis adjustment allowing for improved EPI image quality. The spinScan® spectrometer features Mediso’s extensive pulse sequence library with a wide range of readily optimized imaging protocols including all relevant anatomical sequences as well as high-end neuroimaging and spectroscopy protocols.

The console creates a future proof platform for all nanoScan® MRI systems, especially empowering the standalone MRI’s used for high-end preclinical research applications.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

LumiGuide, powered by Fiber Optic RealShape (FORS) technology, enables doctors to navigate through blood vessels using light, instead of X- ray. “[It’s] one of the most exciting changes that we’ve seen with imaging certainly throughout my career,” said Andres Schanzer, Vascular Surgeon, at UMass Memorial Medical Center, Worcester, MA, USA.
Carestream Health notes twenty-seven of the patents were awarded by the U.S. Patent and Trademark Office; an additional 43 patents were received in European and Asian countries.
According to an Insightec study, patients experienced significant reductions in upper limb tremor, tremor-related disability, and quality of life. The most common intraprocedural adverse events included dizziness, headache, nausea, and vomiting, which all resolved. Post-procedural adverse events included paraesthesia and gait disturbance, which were often transient or resolved within 12 months.
Chris Landon, Business Leader Image Guided Therapy Devices at Philips: “IVUS is a technology that has demonstrated an ability to both support safer procedures for patients and procedural staff alike including reductions in radiation exposure. As the global leader in IVUS solutions, we are grateful for the rigorous multidisciplinary approach to developing expert consensus on the value of IVUS and we look forward to working with all stakeholders to standardize the use of IVUS and reduce the barriers preventing utilization.”
"We are delighted to see our 3D solution CE-marked and available on the European market," says Ulrik Harrysson, CEO at SyntheticMR AB. "SyMRI 3D represents the next generation of quantitative MRI, offering unprecedented resolution and accuracy in brain imaging, revolutionizing the landscape of medical diagnostics."

By using this website you agree to accept Medical Device News Magazine Privacy Policy